These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20816250)

  • 1. Microplasmin for vitreomacular traction.
    Udaondo P; Diaz-Llopis M; Garcia-Delpech S; Salom D; Arevalo JF
    Ophthalmology; 2010 Sep; 117(9):1859, 1859.e1; author reply 1859-60. PubMed ID: 20816250
    [No Abstract]   [Full Text] [Related]  

  • 2. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial.
    de Smet MD; Gandorfer A; Stalmans P; Veckeneer M; Feron E; Pakola S; Kampik A
    Ophthalmology; 2009 Jul; 116(7):1349-55, 1355.e1-2. PubMed ID: 19447497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Injectable drug may help avoid eye surgery in patients with vitreomacular adhesion.
    Morrow T
    Manag Care; 2013 Jan; 22(1):49-50. PubMed ID: 23373143
    [No Abstract]   [Full Text] [Related]  

  • 4. Microplasmin before vitrectomy.
    Narayanan R; Dave V
    Ophthalmology; 2011 Feb; 118(2):428-9; author reply 429. PubMed ID: 21292118
    [No Abstract]   [Full Text] [Related]  

  • 5. A placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy.
    Benz MS; Packo KH; Gonzalez V; Pakola S; Bezner D; Haller JA; Schwartz SD
    Ophthalmology; 2010 Apr; 117(4):791-7. PubMed ID: 20138368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How should we release vitreomacular traction: surgically, pharmacologically, or pneumatically?
    Johnson MW
    Am J Ophthalmol; 2013 Feb; 155(2):203-205.e1. PubMed ID: 23312439
    [No Abstract]   [Full Text] [Related]  

  • 7. Looking at ocriplasmin as a new option in eye disease.
    Mitchell MD; Miller DM
    Drugs Today (Barc); 2012 Aug; 48(8):519-24. PubMed ID: 22916339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral nonrhegmatogenous retinal detachment associated with vitreomacular traction syndrome.
    Georgalas I; Koutsandrea C; Papaconstantinou D; Karagiannis D; Ladas I
    Can J Ophthalmol; 2010 Aug; 45(4):418-9. PubMed ID: 20436533
    [No Abstract]   [Full Text] [Related]  

  • 9. Vitreomacular adhesion in active and end-stage age-related macular degeneration.
    Holekamp NM
    Am J Ophthalmol; 2010 Jan; 149(1):171-2; author reply 172-3. PubMed ID: 20103042
    [No Abstract]   [Full Text] [Related]  

  • 10. Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded?
    Manousaridis K; Peter S; Mennel S
    Acta Ophthalmol; 2018 May; 96(3):e409-e411. PubMed ID: 28771974
    [No Abstract]   [Full Text] [Related]  

  • 11. Tangential vitreous traction observed in optic disc pit maculopathy without apparent serous detachment.
    Joko T; Kusaka S
    Ophthalmic Surg Lasers; 1998 Aug; 29(8):677-9. PubMed ID: 9715494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microplasmin-assisted vitrectomy.
    Gandorfer A
    Dev Ophthalmol; 2009; 44():26-30. PubMed ID: 19494649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knowledge of vitreomacular traction (VMT) scenarios: Is doing nothing still a beneficial alternative and, if so, when?
    Ziemssen F; Bartz-Schmidt KU; Dimopoulos S
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):615-6. PubMed ID: 26887826
    [No Abstract]   [Full Text] [Related]  

  • 14. Detecting vitreomacular adhesions in eyes with asteroid hyalosis with triamcinolone acetonide.
    Yamaguchi T; Inoue M; Ishida S; Shinoda K
    Graefes Arch Clin Exp Ophthalmol; 2007 Feb; 245(2):305-8. PubMed ID: 16411097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathology of Internal Limiting Membrane Specimens Following Intravitreal Injection of Ocriplasmin.
    Schumann RG; Wolf A; Mayer WJ; Compera D; Hagenau F; Ziada J; Kampik A; Haritoglou C
    Am J Ophthalmol; 2015 Oct; 160(4):767-78. PubMed ID: 26133247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocriplasmin (Jetrea) for vitreomacular adhesion.
    Med Lett Drugs Ther; 2013 Aug; 55(1422):63-4. PubMed ID: 23917386
    [No Abstract]   [Full Text] [Related]  

  • 17. Ocriplasmin for vitreoretinal diseases.
    Tsui I; Pan CK; Rahimy E; Schwartz SD
    J Biomed Biotechnol; 2012; 2012():354979. PubMed ID: 23193358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research update of ocriplasmin for symptomatic vitreomacular adhesion].
    Zhang M; Chen Y
    Zhonghua Yan Ke Za Zhi; 2014 Nov; 50(11):866-70. PubMed ID: 25582211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel possibility of vitreomacular traction treatment.
    Michalska-Małecka K; Witek K; Sierocka-Stępień J; Wyględowska-Promieńska D; Nowak M
    Acta Ophthalmol; 2016 Dec; 94(8):e818-e819. PubMed ID: 27167161
    [No Abstract]   [Full Text] [Related]  

  • 20. The Efficacy and Safety Profile of Ocriplasmin in Vitreomacular Interface Disorders.
    Shaikh M; Miller JB; Papakostas TD; Husain D
    Semin Ophthalmol; 2017; 32(1):52-55. PubMed ID: 27786583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.